Microfluidic Vortex Shedding: A New Approach for CRISPR Delivery and Engineering T Cells

In this video, Justin Jarrell, VP of Research at Indee Labs, talks about microfluidic vortex shedding as a platform for non-viral based transfection for development and manufacturing of T cell immunotherapies. The Indee Labs team demonstrated the successful transfection and CRISPR editing of T cells in their recent paper. Related Resources: Blog summary of the paper: https://www.synthego.com/blog/microfl... Cited Publications Database: https://www.synthego.com/publications Featured Researchers: https://www.synthego.com/customers Learn More About Synthego: https://www.synthego.com Subscribe Now to The Bench Blog: https://www.synthego.com/blog Schedule a Free CRISPR Assessment: https://www.synthego.com/discovery SYNTHEGO ON SOCIAL:   / synthego     / synt.  .   / synthego   ABOUT SYNTHEGO Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. #CRISPRResearch